Welcome to our dedicated page for ProKidney news (Ticker: PROK), a resource for investors and traders seeking the latest updates and insights on ProKidney stock.
ProKidney Corp. (Nasdaq: PROK) generates frequent news flow as a late clinical-stage biotechnology company focused on chronic kidney disease (CKD) and autologous cellular therapy. News coverage for ProKidney often centers on clinical trial milestones for its lead product candidate, rilparencel (also known as REACT®), regulatory interactions with the U.S. Food and Drug Administration (FDA), and financial and corporate updates relevant to investors following PROK stock.
Readers can expect updates on Phase 2 and Phase 3 studies, including the REGEN-007 and REGEN-006 (PROACT 1) trials in patients with advanced CKD and diabetes. Press releases have highlighted statistically significant and clinically meaningful changes in estimated glomerular filtration rate (eGFR) slope, safety findings such as the absence of rilparencel-related serious adverse events in reported analyses, and FDA confirmation that eGFR slope can serve as a surrogate endpoint for an accelerated approval pathway. These items help investors and observers track the progress of rilparencel through late-stage development.
ProKidney news also includes quarterly financial results, cash runway commentary, and disclosures about research and development and general and administrative expenses. SEC-related announcements, such as at-the-market equity offering arrangements and changes in jurisdiction of incorporation, are commonly reported through press releases and associated Form 8-K filings. In addition, the company regularly announces participation in scientific and investor conferences, including American Society of Nephrology Kidney Week presentations and healthcare investment conferences where senior management discusses clinical data and corporate strategy.
For anyone monitoring PROK news, this stream of clinical, regulatory, financial, and conference-related updates provides insight into ProKidney’s efforts to advance rilparencel as a potential new treatment option for patients with advanced CKD and diabetes and to manage the company’s capital and public market presence.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ProKidney Corp. (Nasdaq: PROK) announced its fourth quarter 2022 financial results, reporting a net loss of $24.6 million, compared to $13.7 million in Q4 2021. The company has made significant strides in clinical development, particularly in its REACT® trials for chronic kidney disease, with key milestones anticipated in 2023. Their cash position stands at $490.3 million, bolstered by a PIPE financing that raised over $500 million. R&D expenses rose to $20.9 million, driven by intensified clinical activities. G&A expenses also increased to $9.3 million, influenced by public company costs. The company expects to fund operations through 2024, aiming for topline data from proact1.
ProKidney Corp. (Nasdaq: PROK), a leader in cellular therapeutics for chronic kidney disease (CKD), announced that CEO Dr. Tim Bertram will present at TD Cowen’s 43rd Annual Health Care Conference on March 7, 2023, at 10:30 AM EST. Investors can access the live webcast on ProKidney’s investor relations site. The company’s groundbreaking product, REACT™, is a patented therapy aimed at treating late-stage CKD, having received Regenerative Medicine Advanced Therapy designation and FDA guidance. ProKidney, founded in 2015, highlights the critical need for effective CKD treatments, given the high mortality rates associated with late-stage CKD.
ProKidney Corp. (Nasdaq: PROK) announced the publication of early data analysis from its Phase 2 clinical trial, REGEN-003, in the Journal of Blood Purification. The study evaluates the effectiveness of Renal Autologous Cell Therapy (REACT) in patients with late-stage diabetic kidney disease. Participants demonstrated a mean dialysis delay of 16 months, with 20% preserving their kidney function after 15 months. The trial focuses on patients unlikely to qualify for transplants, marking a significant step in CKD treatment. ProKidney emphasizes the potential of REACT to improve quality of life for patients.
ProKidney Corp. (Nasdaq: PROK), a leader in cellular therapeutics for chronic kidney disease (CKD), will have its CEO, Dr. Tim Bertram, present at the J.P. Morgan 41st Annual Healthcare Conference on January 11, 2023, at 3:45 PM PT in San Francisco. The webcast will be accessible via their investor relations website. ProKidney is known for its innovative REACT® therapy aimed at preserving kidney function in late-stage CKD, having received FDA's Regenerative Medicine Advanced Therapy designation. CKD affects over 75 million people in the U.S. and Europe.
ProKidney Corp. (Nasdaq: PROK) announced its Q3 2022 financial results, reporting a net loss of $33.9 million, up from $17.1 million in Q3 2021. The company ended the quarter with $506.3 million in cash, following a successful Nasdaq listing that raised $512 million. ProKidney is advancing its REACT® clinical program, with ongoing Phase 3 studies, proact 1 and proact 2, aimed at chronic kidney disease (CKD) treatment. The company anticipates initial data from its Phase 2 study (REGEN-007) by mid-2023. Significant corporate developments include favorable advice from the EMA and the commencement of patient recruitment in the UK.
ProKidney Corp. (Nasdaq: PROK) announced that CEO Dr. Tim Bertram will participate in upcoming investor conferences, including the Jefferies London Healthcare Conference on November 16, 2022, and the Evercore ISI 5th Annual HEALTHCONx Virtual Conference on December 1, 2022. Both events will feature fireside chats available via webcast on ProKidney’s investor relations website. ProKidney specializes in chronic kidney disease (CKD) treatments, focusing on its groundbreaking REACT® therapy, which has received regulatory designations supporting its Phase 3 clinical program.
FAQ
What is the current stock price of ProKidney (PROK)?
What is the market cap of ProKidney (PROK)?
